DarioHealth Corp. Stock News

Mr. Palumbo to join Dario's third quarter 2026 earnings call to share the Board's view on the convergence of consumer and payer-led healthcare and chronic care management NEW YORK, Nov. 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today ann...

Contract extension follows benefits realized from Dario's cardiometabolic program and strong employee demand for perimenopause support Nearly 45% of Dario's current book of business is women over age 40 who could potentially benefit from Dario Women™ Dario's expanding multi-condition platform addresses a larger share of clients' membership bases, delivering greater value to payers while increas...

A component study of the independent review by Aon found $5,077 in annual savings and 23.5% fewer inpatient discharges per Dario user with type 2 diabetes versus matched non-users Evaluation of 17 studies estimates $3.8 million to $10.8 million in annual savings for a 20,000-life population Aon estimates an additional 1.6 to 2.8 percentage points of potential healthcare cost savings as a result...

Agreement secured through channel partner Amwell significantly expands Dario's reach through its channel distribution strategy Program for Dario's cardiometabolic suite and provider-backed care expected to launch with the customer and begin generating revenue in the first quarter of 2027 Marks the third large state health plan signed through Amwell in the past 12 months, following contracts in ...

Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter Operating loss decreased by 30% year-over-year and 11%...

New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care strategy AI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario's participation in reimbursement-driven h...

First commercial offering from Dario's collaboration with Beluga Health adds licensed provider evaluation, prescribing and ongoing clinical oversight directly inside Dario's chronic care platform Commercial availability expected Fall 2026, with revenue contribution anticipated late 2026 and ramping through 2027 Launch addresses a market in which employers and health plans are reducing GLP-1 cov...